Tag: Boehringer Ingelheim

March 26, 2019

7 Potential Blockbuster Drugs Investors Should Watch for in 2019

A report by Cortellis says that seven drugs entering the market in 2019 are projected to reach blockbuster status by...
November 15, 2018

Boehringer Ingelheim Partners with Epizyme

Boehringer Ingelheim and Epizyme announced a partnership on Thursday to develop oncology treatments.The partnership entails developing, researching and commercializing small...
June 25, 2018

Boehringer Ingelheim and Eli Lilly Share Positive Phase 3 Results

Empaglifozin was used in those trials in combination with traditional insulin therapy to evaluate if it could provide blood sugar...
June 25, 2018

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced that both randomised controlled trials in the EASE phase III...